FUJIFILM：使用iPS治疗眼部疾病：BlueRock许可的技术
-许可给拜耳子公司“ Blue Lock Therapeutics”的技术-
富士胶卷：
5月18日，“使用iPS细胞进行药物发现的许可选择权”，
“它将提供给德国大型制药公司拜耳的美国子公司。”
蓝锁疗法：
Blue Lock正在非临床阶段研究“使用iPS细胞治疗眼部疾病的方法”。
iPS细胞药物发现许可证：
一次性付款总额为7,000万美元（约合76亿日元）。
如果Blue Lock行使期权权利
富士胶片获得约10％的销售特许权使用费。
FCDI和Opsis：
iPS细胞培养和销售子公司：Fujifilm Cellular Dynamics（FCDI），
视网膜疾病开发公司的治疗方法：“ Opsis Therapeutics”，
以上两家公司是药物发现许可证的技术提供者。
三公司合作体系：
“与年龄有关的黄斑变性”和“色素性视网膜炎”
我们的目标是“使用iPS细胞治疗导致失明的难治性眼部疾病”。
日本经济新闻
https://www.nikkei.com/article/DGXZQOUC187BA0Y1A510C2000000/
BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases
Cambridge, Mass., and Madison, Wis. [May 17, 2021]
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG,
FUJIFILM Cellular Dynamics, Inc. a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies,
Opsis Therapeutics, LLC, a joint venture of FUJIFILM Cellular Dynamics (FCDI)
David Gamm, M.D., Ph.D., co-founder, focusing on developing cell therapies for patients with ocular diseases,
today announced that they have entered into a strategic research and development (R&D) alliance.
As part of the alliance,
the companies will combine their collective expertise to discover and develop off-the-shelf iPS cell therapies for ocular diseases.
Under this agreement,
BlueRock Therapeutics
will have the option to exclusively license from both parties three (3) retinal cell therapy programs focused on
dry age-related macular degeneration (AMD)
inherited retinal diseases (IRDs) containing human retinal pigment epithelial cells
photoreceptor cells, currently in pre-clinical development.
BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases
Cambridge, Mass., and Madison, Wis. [May 17, 2021]
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG,
FUJIFILM Cellular Dynamics, Inc. a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies,
Opsis Therapeutics, LLC, a joint venture of FUJIFILM Cellular Dynamics (FCDI)
David Gamm, M.D., Ph.D., co-founder, focusing on developing cell therapies for patients with ocular diseases,
today announced that they have entered into a strategic research and development (R&D) alliance.
As part of the alliance,
the companies will combine their collective expertise to discover and develop off-the-shelf iPS cell therapies for ocular diseases.
Under this agreement,
BlueRock Therapeutics
will have the option to exclusively license from both parties three (3) retinal cell therapy programs focused on
dry age-related macular degeneration (AMD)
inherited retinal diseases (IRDs) containing human retinal pigment epithelial cells
photoreceptor cells, currently in pre-clinical development.
“Millions of patients around the world today are suffering from permanent vision loss as a result of incurable ocular diseases,” states Nick Manusos, Chief Executive Officer, Opsis Therapeutics.
Fujifilm [Japan]